drug
sipuleucel-T
Marketedupdated 5mo agoby Dendreon Pharmaceuticals LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying sipuleucel-T
- phase2Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
- phase1Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
- phase2Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
- phase2Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
- phase3Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
News(2)
- 5 drugmakers chasing Merck and Moderna in the cancer vaccine raceFollowing their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…biospace · 20d ago
- mRNA cancer vaccines’ biggest barriers to marketManufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.biopharma_dive · 22d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that